An Adaptive Seamless Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Investigate the Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients
Phase of Trial: Phase II
Latest Information Update: 11 Jan 2019
At a glance
- Drugs LNP-023 (Primary)
- Indications IgA nephropathy
- Focus Proof of concept; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 19 Nov 2018 Planned End Date changed from 15 Oct 2019 to 6 Apr 2021.
- 19 Nov 2018 Planned primary completion date changed from 15 Jul 2019 to 12 Jan 2021.
- 05 Oct 2018 Planned End Date changed from 30 Apr 2019 to 15 Oct 2019.